Recall Radar
All recallsMedicine & devices

DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Class II Medicine & devices FDA July 1, 2026 Reached Texas
Read the official FDA notice →

What to do

Stop using the product and check it against the description above. Follow the remedy on the official notice; most recalls are refunded or replaced without a receipt. If you or a family member has already been affected, keep the packaging and the lot code — they're what a claim rests on later.

Details

Recalling company
Direct Rx — Dawsonville, GA
Severity
Class II — moderate
Reported
July 1, 2026
Quantity
263 Bottles
Recall number
D-0617-2026
Status
Ongoing
Source
FDA

Where it went

U.S. Nationwide

Other medicine & devices recalls

See every current recall on the live dashboard →